Search

Your search keyword '"Buzdar, Aman U"' showing total 1,351 results
Start Over Author "Buzdar, Aman U"
1,351 results on '"Buzdar, Aman U"'

1. Predictive algorithms for adjuvant therapy: TransATAC

Author

Penning, T.M., Dowsett, Mitch, Salter, Janine, Zabaglo, Lila, Mallon, Elizabeth, Howell, Antony, Buzdar, Aman U, Forbes, John, Pineda Sanjuan, Silvia, Cuzick, Jack, Penning, T.M., Dowsett, Mitch, Salter, Janine, Zabaglo, Lila, Mallon, Elizabeth, Howell, Antony, Buzdar, Aman U, Forbes, John, Pineda Sanjuan, Silvia, and Cuzick, Jack

Abstract

Estrogen receptor (ER) positive primary breast cancers have a wide range of clinical outcomes. Prediction of the likely course of the disease aids treatment decision-making. In the translational arm of the ATAC (anastrozole or tamoxifen alone or combined) trial (TransATAC) we have assessed individual and multiparameter biomarkers for their prediction of overall and distant recurrence. None of the biomarkers identified differential benefit for anastrozole versus tamoxifen. Each of ER, PgR, HER2 and Ki67 was associated with risk of recurrence. A combination of these to create a single predictor IHC4 was as informative as the 21-gene recurrence score (RS). Integration of each of these molecular profiles with classical clinicopathologic variables provided the most accurate prediction of outcome, Breakthrough Breast Cancer, AstraZeneca, Depto. de Estadística y Ciencia de los Datos, Fac. de Estudios Estadísticos, TRUE, pub

Published
2024

2. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer

Author

Jack Cuzick, Dowsett, Mitch, Pineda Sanjuan, Silvia, Wale, Christopher, Salter, Janine, Quinn, Emma, Zabaglo, Lila, Mallon, Elizabeth, R Green, Andrew, Ellis, Ian O, Howell, Anthony, Buzdar, Aman U, Forbes, John F, Jack Cuzick, Dowsett, Mitch, Pineda Sanjuan, Silvia, Wale, Christopher, Salter, Janine, Quinn, Emma, Zabaglo, Lila, Mallon, Elizabeth, R Green, Andrew, Ellis, Ian O, Howell, Anthony, Buzdar, Aman U, and Forbes, John F

Abstract

Purpose We recently reported that the mRNA-based, 21-gene Genomic Health recurrence score (GHI-RS) provided additional prognostic information regarding distant recurrence beyond that obtained from classical clinicopathologic factors (age, nodal status, tumor size, grade, endocrine treatment) in women with early breast cancer, confirming earlier reports. The aim of this article is to determine how much of this information is contained in standard immunohistochemical (IHC) markers. Patients and Methods The primary cohort comprised 1,125 estrogen receptor–positive (ER-positive) patients from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial who did not receive adjuvant chemotherapy, had the GHI-RS computed, and had adequate tissue for the four IHC measurements: ER, progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and Ki-67. Distant recurrence was the primary end point, and proportional hazards models were used with sample splitting to control for overfitting. A prognostic model that used classical variables and the four IHC markers (IHC4 score) was created and assessed in a separate cohort of 786 patients. Results All four IHC markers provided independent prognostic information in the presence of classical variables. In sample-splitting analyses, the information in the IHC4 score was found to be similar to that in the GHI-RS, and little additional prognostic value was seen in the combined use of both scores. The prognostic value of the IHC4 score was further validated in the second separate cohort. Conclusion This study suggests that the amount of prognostic information contained in four widely performed IHC assays is similar to that in the GHI-RS. Additional studies are needed to determine the general applicability of the IHC4 score., Royal Marsden National Institute for Health Research Biomedical Research Centre, Cancer Research United Kingdom Program Grant, Breakthrough Breast Cancer, AstraZeneca, Depto. de Estadística y Ciencia de los Datos, Fac. de Estudios Estadísticos, TRUE, pub

Published
2024

5. Supplementary Table from Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer

Author

Yam, Clinton, primary, Abuhadra, Nour, primary, Sun, Ryan, primary, Adrada, Beatriz E., primary, Ding, Qing-Qing, primary, White, Jason B., primary, Ravenberg, Elizabeth E., primary, Clayborn, Alyson R., primary, Valero, Vicente, primary, Tripathy, Debu, primary, Damodaran, Senthilkumar, primary, Arun, Banu K., primary, Litton, Jennifer K., primary, Ueno, Naoto T., primary, Murthy, Rashmi K., primary, Lim, Bora, primary, Baez, Luis, primary, Li, Xiaoxian, primary, Buzdar, Aman U., primary, Hortobagyi, Gabriel N., primary, Thompson, Alistair M., primary, Mittendorf, Elizabeth A., primary, Rauch, Gaiane M., primary, Candelaria, Rosalind P., primary, Huo, Lei, primary, Moulder, Stacy L., primary, and Chang, Jeffrey T., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure from Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer

Author

Yam, Clinton, primary, Abuhadra, Nour, primary, Sun, Ryan, primary, Adrada, Beatriz E., primary, Ding, Qing-Qing, primary, White, Jason B., primary, Ravenberg, Elizabeth E., primary, Clayborn, Alyson R., primary, Valero, Vicente, primary, Tripathy, Debu, primary, Damodaran, Senthilkumar, primary, Arun, Banu K., primary, Litton, Jennifer K., primary, Ueno, Naoto T., primary, Murthy, Rashmi K., primary, Lim, Bora, primary, Baez, Luis, primary, Li, Xiaoxian, primary, Buzdar, Aman U., primary, Hortobagyi, Gabriel N., primary, Thompson, Alistair M., primary, Mittendorf, Elizabeth A., primary, Rauch, Gaiane M., primary, Candelaria, Rosalind P., primary, Huo, Lei, primary, Moulder, Stacy L., primary, and Chang, Jeffrey T., primary

Published
2023
Full Text
View/download PDF

7. Data from Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer

Author

Yam, Clinton, primary, Abuhadra, Nour, primary, Sun, Ryan, primary, Adrada, Beatriz E., primary, Ding, Qing-Qing, primary, White, Jason B., primary, Ravenberg, Elizabeth E., primary, Clayborn, Alyson R., primary, Valero, Vicente, primary, Tripathy, Debu, primary, Damodaran, Senthilkumar, primary, Arun, Banu K., primary, Litton, Jennifer K., primary, Ueno, Naoto T., primary, Murthy, Rashmi K., primary, Lim, Bora, primary, Baez, Luis, primary, Li, Xiaoxian, primary, Buzdar, Aman U., primary, Hortobagyi, Gabriel N., primary, Thompson, Alistair M., primary, Mittendorf, Elizabeth A., primary, Rauch, Gaiane M., primary, Candelaria, Rosalind P., primary, Huo, Lei, primary, Moulder, Stacy L., primary, and Chang, Jeffrey T., primary

Published
2023
Full Text
View/download PDF

10. Endocrine Therapy for Breast Cancer

Author

Pinder, Mary C., Buzdar, Aman U., Buzdar, Aman U., editor, Freedman, Ralph S., editor, Hunt, Kelly K., editor, Robb, Geoffrey L., editor, Strom, Eric A., editor, and Ueno, Naoto T., editor

Published
2008
Full Text
View/download PDF

12. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway

Author

Dudenkov, Tanda M., Ingle, James N., Buzdar, Aman U., Robson, Mark E., Kubo, Michiaki, Ibrahim-zada, Irada, Batzler, Anthony, Jenkins, Gregory D., Pietrzak, Tracy L., Carlson, Erin E., Barman, Poulami, Goetz, Matthew P., Northfelt, Donald W., Moreno-Aspita, Alvaro, Williard, Clark V., Kalari, Krishna R., Nakamura, Yusuke, Wang, Liewei, and Weinshilboum, Richard M.

Published
2017
Full Text
View/download PDF

13. Breast Cancer

Author

Buzdar, Aman U., Buchholz, Thomas A., Taylor, Sarah H., Hortobagyi, Gabriel N., Hunt, Kelly K., Rodriguez, M. Alma, editor, Walters, Ronald S., editor, and Burke, Thomas W., editor

Published
2013
Full Text
View/download PDF

15. Endocrine Therapy for Breast Cancer

Author

Buzdar, Aman U., Buzdar, Aman U., editor, Freedman, Ralph S., editor, Hunt, Kelly K., editor, Robb, Geoffrey L., editor, Strom, Eric A., editor, and Ueno, Naoto T., editor

Published
2001
Full Text
View/download PDF

16. Aromatase

Author

Shaheenah, D, Fellow, Susan G Komen, Buzdar, Aman U., Offermanns, Stefan, editor, and Rosenthal, Walter, editor

Published
2008
Full Text
View/download PDF

17. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

Author

Buzdar, Aman U, Suman, Vera J, Meric-Bernstam, Funda, Leitch, A Marilyn, Ellis, Matthew J, Boughey, Judy C, Unzeitig, Gary, Royce, Melanie, McCall, Linda M, Ewer, Michael S, and Hunt, Kelly K

Published
2013
Full Text
View/download PDF

19. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

Author

Goss, Paul E, Smith, Ian E, O'Shaughnessy, Joyce, Ejlertsen, Bent, Kaufmann, Manfred, Boyle, Frances, Buzdar, Aman U, Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen I, Lindquist, Deborah, Chavarri-Guerra, Yanin, Aktan, Gursel, Rappold, Erica, Williams, Lisa S, and Finkelstein, Dianne M

Published
2013
Full Text
View/download PDF

22. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer

Author

Yam, Clinton, primary, Abuhadra, Nour, additional, Sun, Ryan, additional, Adrada, Beatriz E., additional, Ding, Qing-Qing, additional, White, Jason B., additional, Ravenberg, Elizabeth E., additional, Clayborn, Alyson R., additional, Valero, Vicente, additional, Tripathy, Debu, additional, Damodaran, Senthilkumar, additional, Arun, Banu K., additional, Litton, Jennifer K., additional, Ueno, Naoto T., additional, Murthy, Rashmi K., additional, Lim, Bora, additional, Baez, Luis, additional, Li, Xiaoxian, additional, Buzdar, Aman U., additional, Hortobagyi, Gabriel N., additional, Thompson, Alistair M., additional, Mittendorf, Elizabeth A., additional, Rauch, Gaiane M., additional, Candelaria, Rosalind P., additional, Huo, Lei, additional, Moulder, Stacy L., additional, and Chang, Jeffrey T., additional

Published
2022
Full Text
View/download PDF

27. SNP biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer

Author

Ingle, James N., Kalari, Krishna R., Barman, Poulami, Shepherd, Lois E., Ellis, Matthew J., Goss, Paul E., Buzdar, Aman U., Robson, Mark E., Cairns, Junmei, Carlson, Erin E., Casey, Abraham Eyman, Hoskin, Tanya L., Goodnature, Barbara A., Haddad, Tufia C., Goetz, Matthew P., Weinshilboum, Richard M., and Wang, Liewei

Subjects
Adult, Estradiol, Aromatase Inhibitors, Estrone, Genome, Human, Breast Neoplasms, Anastrozole, Middle Aged, Polymorphism, Single Nucleotide, Article, Neoplasm Proteins, Humans, Female, Genetic Predisposition to Disease, Neoplasm Recurrence, Local, Genome-Wide Association Study
Abstract

OBJECTIVE: Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/mL and 0.5 pg/mL, respectively, after six months of adjuvant anastrozole therapy had a 3-fold risk of recurrence, we aimed to identify a SNP-based model that would predict elevated E1 and E2 and then validate it in an independent dataset. PATIENTS AND METHODS: The test set consisted of 322 women from the M3 study and the validation set consisted of 152 patients from MA.27. All patients were treated with adjuvant anastrozole, had on-anastrozole E1 and E2 concentrations, and genome-wide genotyping. RESULTS: SNPs were identified from the M3 genome-wide association study. The best model to predict the E1-E2 phenotype with high balanced accuracy was a support vector machine (SVM) model using clinical factors plus 46 SNPs. We did not have an independent cohort that is similar to the M3 study with clinical, E1-E2 phenotypes, and genotype data to test our model. Hence we chose a nested matched case-control cohort (MA.27 study) for testing. Our E1-E2 model was not validated but we found the MA.27 validation cohort was both clinically and genomically different. CONCLUSION: We identified a SNP-based model that had excellent performance characteristics for predicting the phenotype of elevated E1 and E2 in women treated with anastrozole. This model was not validated in an independent dataset but that dataset was clinically and genomically substantially different. The model will need validation in a prospective study.

Published
2021

34. Breast Cancer

Author

Buzdar, Aman U., primary, Buchholz, Thomas A., additional, Taylor, Sarah H., additional, Hortobagyi, Gabriel N., additional, and Hunt, Kelly K., additional

Published
2012
Full Text
View/download PDF

36. TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression

Author

Liu, Mohan, Ingle, James N., Fridley, Brooke L., Buzdar, Aman U., Robson, Mark E., Kubo, Michiaki, Wang, Liewei, Batzler, Anthony, Jenkins, Gregory D., Pietrzak, Tracy L., Carlson, Erin E., Goetz, Matthew P., Northfelt, Donald W., Perez, Edith A., Williard, Clark V., Schaid, Daniel J., Nakamura, Yusuke, and Weinshilboum, Richard M.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results